Anthropic buys Mithril Medicine, a one-person muscular dystrophy biotech that used Claude, price undisclosed

Anthropic's post "Early progress on accelerating drug development with Claude", dated 27 October 2026, says Anthropic has acquired Mithril Medicine.

We’ve acquired Mithril Medicine, a one-person company that has been developing treatments for two rare forms of muscular dystrophy.

Anthropic describes Mithril Medicine as a one-person company that has been developing treatments for two rare forms of muscular dystrophy.

a one-person company that has been developing treatments for two rare forms of muscular dystrophy

Anthropic's post does not state the terms of the Mithril Medicine acquisition.

We’ve acquired Mithril Medicine, a one-person company that has been developing treatments for two rare forms of muscular dystrophy. Its founder, Cody Tranbarger, used Claude to organize contracts

Anthropic says Mithril's founder, Cody Tranbarger, used Claude to organize contracts, logistics, and experiments with 11 external labs, and delegated many other aspects of Mithril's operations to Claude.

Its founder, Cody Tranbarger, used Claude to organize contracts, logistics, and experiments with 11 external labs, and delegated many other aspects of Mithril’s operations to Claude.

Anthropic says Mithril took a possible treatment for one form of muscular dystrophy from an idea to promising results in mice in less than 18 months.

Mithril took a possible treatment for one form of muscular dystrophy from an idea to promising results in mice in less than 18 months.

Anthropic's post names Claude as the system used and does not name a model version for the Mithril work.

Its founder, Cody Tranbarger, used Claude to organize contracts, logistics, and experiments with 11 external labs

Anthropic says Cody Tranbarger is now at Anthropic, is continuing this research, and plans to start several new programs.

Now at Anthropic, Cody is continuing this research, and plans to start several new programs.

Anthropic says that if his drug candidates continue to hold up, it expects a drug to be ready to start clinical trials in humans as soon as late 2028.

If his drug candidates continue to hold up, we expect a drug to be ready to start clinical trials in humans as soon as late 2028.

Anthropic says its research so far is mostly preclinical, meaning for the most part it is not yet at the stage where drugs are tested in humans.

so far it is mostly preclinical— that is, for the most part, it isn’t yet at the stage where the drugs are being tested in humans.

Anthropic says its scientists engaged in research partnerships with six organizations developing new medicines: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group.

our scientists have engaged in deep research partnerships with six organizations developing new medicines: BigHat Biosciences , Bristol Myers Squibb , Divergence Labs , Enveda , Generate Biomedicines , and The Column Group .

Anthropic says it plans to scale up its drug development work substantially.

We plan to scale this work up substantially from here .

Anthropic says it has also started drug discovery efforts of its own, including programs for rare childhood forms of muscular dystrophy where Claude handles much of the scientific and operational work.

We’ve also started drug discovery efforts of our own, including programs for rare childhood forms of muscular dystrophy, where Claude handles much of the scientific and operational work.